Optodrop-Co (Dorzolamide Hydrochloride, Timolol Maleate)

Dorzolamide Hydrochloride, the active ingredient in Optodrop-Co, is a carbonic anhydrase inhibitor presented as an eye‑drop solution for ocular (topical) use. It reduces intra‑ocular pressure in patients with primary open‑angle glaucoma or ocular hypertension. By inhibiting aqueous humor production, it helps preserve visual function in affected individuals.

GNH USA supplies Optodrop-Co as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and global markets. The company provides reliable logistics and documentation support for cross‑border procurement.

Optodrop-Co, a combination antiglaucoma eye‑drop, is used to manage conditions that involve elevated intra‑ocular pressure.

- Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces pressure to prevent conversion to glaucoma. - Secondary glaucoma (e.g., pigmentary or pseudoexfoliative): helps control pressure when monotherapy is insufficient.

Common Side Effects: - Eye irritation or burning sensation: mild discomfort after instillation. - Bitter taste: transient metallic taste due to nasolacrimal drainage. - Blurred vision: temporary visual disturbance. - Eyelid edema: mild swelling of the eyelid. - Conjunctival hyperemia: redness of the eye. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: rare but serious skin reaction. - Marked bradycardia: significant slowing of heart rate. - Bronchospasm: breathing difficulty, especially in asthmatic patients. - Systemic beta‑blocker effects: fatigue, hypotension, or dizziness. - Vision loss: abrupt loss of vision requiring immediate medical attention.

Before using Optodrop-Co, consider the following precautions: - Cardiac assessment: avoid in patients with severe bradycardia, heart block, or uncontrolled heart failure. - Respiratory status: contraindicated in patients with asthma or chronic obstructive pulmonary disease. - Diabetes monitoring: beta‑blocker may mask hypoglycaemia symptoms. - Pregnancy and lactation: use only if clearly needed; safety data are limited. - Drug interactions: review concomitant medications for beta‑blocker or carbonic anhydrase inhibitor interactions. - Store at room temperature: keep in the original container, protect from light and moisture.

Optodrop-Co may interact with several systemic and ocular agents.

Major Interactions (Avoid): - Other non‑selective beta‑blockers: additive cardiac depression. - Systemic beta‑agonists (e.g., albuterol): antagonistic effect on bronchodilation. - Calcium channel blockers: increased risk of heart block. - Antihypertensive agents: excessive lowering of blood pressure. - MAO inhibitors: potential for severe hypotension.

Moderate Interactions (Monitor Closely): - Other carbonic anhydrase inhibitors: enhanced reduction of aqueous humor. - Topical ocular anesthetics: may increase ocular irritation. - Systemic steroids: may affect intra‑ocular pressure control. - Anticholinergic eye drops: possible additive effect on pupil size. - Diuretics: monitor electrolyte balance and renal function.